NR1D1 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-31. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
These locales have a large amount of verticality, the player being able to travel from "roof to balcony to street level", and are rendered with more detail than was previously seen in games like Dishonored.
Transferrin receptor 2 (TfR2) is a protein that in humans is encoded by the TFR2 gene. This protein is involved in the uptake of transferrin-bound iron into cells by endocytosis, although its role is minor compared to transferrin receptor 1.
=== Other mammalian research === The largest mammal-like tracks from the Lower Cretaceous strata from Gondwana reported to date are described from the Botucatu Formation (Brazil) by Buck et al. (2026), expanding known size range of Early Cretaceous mammaliaforms. Redescription and a study on the affinities of Buginbaatar transaltaiensis is published by Lopatin & Averianov (2026). Lopatin & Averianov (2026) report the first discovery of fossil material of multituberculates belonging to the group Djadochtatherioidea from the Upper Cretaceous Nemegt Formation (Mongolia). New information on the endocranial anatomy of Kryptobaatar dashzevegi is provided by Macrini & Rowe (2026). Krause et al. (2026) identify fossil material of "Kimbetopsalis" simmonsae from the Paleocene strata of the Denver Formation (Colorado, United States), extending known geographical range of this species, and transfer the studied species to the genus Taeniolabis. Bishop & Pierce (2026) reconstruct the musculature of the forelimbs five non-therian synapsids, including Vincelestes neuquenianus.
== Animal welfare == Taco Bell is subject to the animal welfare standards of its parent company, Yum! Brands. In 2016, Taco Bell stopped sourcing eggs from egg-laying hens raised in battery cages in their US restaurants. In 2024, Taco Bell announced that it would publish benchmarks on moving away from gestation crates in pork production by the end of 2024. However, no such benchmarks were published that year.
Sources: en.wikipedia.org
=== Endocrine perspective === The endocrine reproductive system becomes functional by the end of the first trimester of fetal life. The testes and ovaries become briefly inactive around the time of birth but resume hormonal activity until several months after birth, when incompletely understood mechanisms in the brain begin to suppress the activity of the arcuate nucleus. This has been referred to as maturation of the prepubertal "gonadostat", which becomes sensitive to negative feedback by sex steroids. The period of hormonal activity until several months after birth, followed by suppression of activity, may correspond to the period of infant sexuality, followed by a latency stage, which Sigmund Freud described. Neurons of the arcuate nucleus secrete gonadotropin releasing hormone (GnRH) into the blood of the pituitary portal system. An American physiologist, Ernst Knobil, found that the GnRH signals from the hypothalamus induce pulsed secretion of LH (and to a lesser degree, FSH) at roughly 1–2 hour intervals. The LH pulses are the consequence of pulsatile GnRH secretion by the arcuate nucleus that, in turn, is the result of an oscillator or signal generator in the central nervous system ("GnRH pulse generator"). In the years preceding physical puberty, Robert M. Boyar discovered that the gonadotropin pulses occur only during sleep, but as puberty progresses they can be detected during the day. By the end of puberty, there is little day-night difference in the amplitude and frequency of gonadotropin pulses.
== Registration of PKMM rejected == In 1950, the Federation of Malaya Government rejected the registration of the Malay Nationalist Party of Malaya (Parti Kebangsaan Melayu Malaya, PKMM) as a legitimate political party. PKMM had two wings, namely Angkatan Pemuda Insaf and Angkatan Wanita Sedar. Initially, PKMM did not have communist leanings. After Mokhtaruddin Lasso was elected as the first PKMM president in October 1946, this party was influenced with communism. The Young Malays Union (Kesatuan Melayu Muda, KMM) merged with PKMM, and Burhanuddin al-Helmy became the second PKMM president. Burhanuddin led PKMM toward the formation of Melayu Raya, a merger of Indonesia and Malaya. In December 1947, Ishak Haji Mohamed became the third PKMM president and PKMM switched from communism to nationalism. PKMM tended against United Malays National Organisation (UMNO) and colonisation. PKKM established the Pusat Tenaga Rakyat (PUTERA), a conglomeration of radical Malay Political Parties and then merged with the All-Malaya Council of Joint Action (AMCJA) which thoroughly opposed the 1948 Federation Agreement for the foundation of the Federation of Malaya. PKMM accused officials selected in the Federation of Malaya of being "puppets" of the "Colonial Office". For PKMM, there was no basis in "preparing Malaya as a democratic government".
== Education and academic career == Ben-Tal studied biology, chemistry, and physics at the Hebrew University of Jerusalem, receiving his bachelor's degree in 1988. He subsequently earned a D.Sc. in chemistry from the Technion – Israel Institute of Technology in 1993, under the supervision of Professor Nimrod Moiseyev. He completed postdoctoral training with Professor Barry Honig in biophysical chemistry and computational biophysics at Columbia University in New York. In 1997, Ben-Tal joined the Department of Biochemistry and Molecular Biology at Tel Aviv University. He became a full professor in 2007. He is a member of the university's School of Neurobiology, Biochemistry and Biophysics and also serves as head of the Bioinformatics Master program within the Faculty of Life Sciences. In 2018, Ben-Tal was awarded the Abraham E. Kazan Chair of Structural Biology at Tel Aviv University.
=== Advanced treatment plant technology === For some emerging contaminants, several advanced technologies—sonolysis, photocatalysis, Fenton-based oxidation and ozonation—have treated pollutants in laboratory experiments. Another technology is "enhanced coagulation" in which the treatment entity would work to optimize filtration by removing precursors to contamination through treatment. In the case of THMs, this meant lowering the pH, increasing the feed rate of coagulants, and encouraging domestic systems to operate with activated carbon filters and apparatuses that can perform reverse osmosis. Although these methods are effective, they are costly, and there have been many instances of treatment plants being resistant to pay for the removal of pollution, especially if it wasn't created in the water treatment process as many EC's occur from runoff, past pollution sources, and personal care products. It is also difficult to incentivize states to have their own policies surrounding contamination because it can be burdensome for states to pay for screening and prevention processes. There is also an element of environmental injustice, in that lower income communities with less purchasing and political power cannot buy their own system for filtration and are regularly exposed to harmful compounds in drinking water and food. However, recent treads for light-based systems shows great potential for such applications. With the decrease in cost of UV-LED systems and growing prevalence of solar powered systems, it shows great potential to remove CEC while keeping costs low.
== Discovery == The discovery of KLB represents an example of a “genome mining” approach. Cluster of genes encoding KLB biosynthetic pathway was found in genome database using low-level homology of one of the proteins to microcin B17 synthetase. Cloning and expression of cluster in a heterologous host (Escherichia coli) yielded the active compound. The name given to the compound reflects the original bacterium where the biosynthetic cluster was found (Klebs-) and the presence of azole cycles (-azolicin).
Sources: en.wikipedia.org
== Acquisitions == In July 2016, Relief acquired FirstString Research, a clinical-stage biotech firm based in Charleston, South Carolina, US. In January 2021, Relief acquired German-based firm AdVita in a €25 million agreement to further their research into inhaled treatments for Acute respiratory distress syndrome. In May 2021, Relief acquired Swiss biotech firm Applied Pharma Research (APR), including its existing portfolio and all pipeline products, for CHF 72 million ($79 million).
Next to the Turin Cathedral stand the Palatine Towers, an ancient Roman-medieval structure that served as one of four Roman city gates along the city walls of Turin. This gate allowed access from north to the cardo maximus, the typical second main street of a Roman town. The Palatine Towers are among the best preserved Roman remains in northern Italy. Close to this site, the 51,300 m2 (552,189 sq ft) Piazza della Repubblica plays host to the biggest open market in Europe, locally known as mercato di Porta Palazzo (Porta Palazzo or Porta Pila are the historical and local names of this area).
=== 9 January === Russia and Ukraine conducted their 36th prisoner swap of the conflict, with each side trading 50 POWs to the other. Ukraine's regional prosecutor's office claimed that an S-300 fired from Belgorod Oblast hit a market in Shevchenkove, killing two women, wounding a child, and damaging a shopping centre. A spokesperson stated that Germany had no plans to provide the Leopard 2 to Ukraine.
=== Cross-linking micelles === Polymer-based micelles that undergo crosslinking reactions can induce the formation of nanogels. Crosslinking either the core or the shell of a preexisting micelles can synthesize nanogels with a "high degree of spatial organization".
Mammalian alcohol dehydrogenases also have a structural zinc site. This Zn ion plays a structural role and is crucial for protein stability. The structures of the catalytic and structural zinc sites in horse liver alcohol dehydrogenase (HLADH) as revealed in crystallographic structures, which has been studied computationally with quantum chemistry as well as with classical molecular dynamics methods. The structural zinc site is composed of four closely spaced cysteine ligands (Cys97, Cys100, Cys103, and Cys111 in the amino acid sequence) positioned in an almost symmetric tetrahedron around the Zn ion. A recent study showed that the interaction between zinc and cysteine is governed by primarily an electrostatic contribution with an additional covalent contribution to the binding.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.